Citable company snapshot
Pfizer's latest SEC-sourced 2026-03-29 period shows $14.45B in revenue and $2.69B in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:Revenues | Mar 29, 2026 | $14.45B | $17.56B | -17.7% |
| xbrl:NetIncomeLoss | Mar 29, 2026 | $2.69B | $-1.65B | +263.1% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 29, 2026 | $2.62B | $5.35B | -51.1% |
| Free Cash Flow (computed) | Mar 29, 2026 | $2.18B | $4.50B | -51.6% |
Source: SEC EDGAR XBRL; period Mar 29, 2026; filed May 5, 2026; accession 0000078003-26-000054.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
